Among other major losers, NEXON is plummeting almost 14 percent and Sumitomo Metal Mining is sliding almost 8 percent, while Daiichi Sankyo and JGC Holdings are ... Elsewhere in Asia, South Korea is ...

KT&G Corporation ("KT&G" or the "Company") (KRX:033780), announced the 'KT&G Corporate Value-up Plan' on the 7th, that includes their goal of achieving 15% ROE and returning KRW 3.7 trillion to ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

The NHS often relies on professional interpreters and translation services to bridge these gaps, but this comes at a financial cost. Investing in language training for healthcare professionals could ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

SEOUL, South Korea — North Korea launched an intercontinental ballistic missile for the first time in almost a year Thursday in a test of what may be a new, more agile weapon targeting the ...

Artificial intelligence “will acquire a human form,” a senior official at US chipmaker Nvidia told an event in Tokyo on ...